Navigation Links
Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Date:9/30/2009

mprove liquidity in our common stock and improve our access to the capital markets. In the coming months, we hope to announce several important milestones. By the end of 2009, we expect to announce clinical trial data on our lead product candidate, DR Cysteamine, from a Phase 2a clinical trial in non-alcoholic steatohepatitis ("NASH") and a Phase 2b clinical trial in nephropathic cystinosis ("cystinosis")."

In connection with the exchange of shares in the merger, Raptor and TorreyPines stockholders will own 95% and 5% of the outstanding shares of the combined company, respectively. Raptor stockholders will receive 17,881,300 shares of the combined company's common stock in exchange for the 76,703,147 shares of Raptor common stock outstanding immediately prior to the closing of the merger. TorreyPines stockholders will receive 941,121 shares of the combined company's common stock in exchange for the 15,999,058 shares of TorreyPines common stock outstanding immediately prior to the closing of the merger. For example:


                                          1,000 Shares of    1,000 Shares of
                                              Raptor           TorreyPines
                                          ---------------    ---------------
    Number of Combined Company Shares
     Issued as a Result of Merger              233                 58


In connection with the merger and subject to the same conversion factor as the Raptor common stock, the combined company will assume all of Raptor's stock options and warrants outstanding at the time of the merger. The combined company will also retain the TorreyPines stock options and warrants outstanding at the merger, subject to the same conversion factor as the TorreyPines common stock.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. ("the Company") is dedicated to speeding the de
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.; TorreyPines Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
2. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
3. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. Raptor Pharmaceuticals Provides Update on Targeting Platforms
7. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
8. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
9. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
10. Raptor Pharmaceuticals Provides Update of Product Programs
11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... , REDWOOD CITY, Calif., Dec. 24 Maxygen, Inc. ... development of improved versions of protein drugs, today announced the ... expired at 5:00 p.m., New York City time, on December ... by the depositary for the tender offer, Maxygen expects to ...
... , , GREENSBORO, N.C., Dec. 23 ... four users who allege kidney damage due to the use ... in preparation for a colonoscopy. (Holshouser et al v. ... are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., ...
Cached Medicine Technology:Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2Suits Commenced Against Maker of Prescription Cleansing Drug 2
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay ... kids as unhealthy or recognize the health consequences of excess ... children of the families surveyed for the new research were ... Providence, R.I. "A third categorized their child,s health as ... now an assistant professor of pediatrics at the University of ...
(Date:7/24/2014)... University School of Medicine researchers may have found a ... They discovered that pre-treatment of neurons with the anti-aging ... of the toxic amyloid protein and glutamate. These findings ... . , Alzheimer,s disease is the most frequent ... of people age 65 and older and more than ...
(Date:7/24/2014)... 2014 News Facts , Lexmark’s ... achieved certification for compliance with Department of Defense ... the DoD Information Assurance Certification and Accreditation Process ... within the DoD as the Enterprise Clinical Imaging ... from the U.S. Army Medical Materiel Agency. , ...
(Date:7/24/2014)... choosing between two or more equally positive outcomes ... associated with activity in different regions of the ... an associate research scholar at the Princeton Neuroscience ... experiment, 42 people rated the desirability of more ... they looked at images of paired products with ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 Horizon ... will give one lucky family a rent-free week in ... until August 3, 2014. Don’t miss your chance to ... sweepstakes is open to all New Jersey residents, 25 ... BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , “A ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... adults who are heavy users of marijuana are ... development, according to a new study. Pediatric researchers ... interconnect brain regions involved in memory, attention, decision-making, ... of particular concern because adolescence is a crucial ...
... 2 The Spastic Paraplegia Foundation (SPF) is ... (PLS) Awareness Month, part of a national effort ... that affects tens of thousands of families across ... )"It is important that we create greater awareness ...
... Totally-Endoscopic Coronary Artery Bypasses (Tecab) , ATLANTA Feb. 2 ... MD, the pioneer and world leader in performing beating ... staff at Saint Joseph,s Hospital in Atlanta. Dr. Srivastava ... Medical Center where he served as assistant professor ...
... Fellowship" to Focus on Auto Safety AdvocacyWASHINGTON, Feb. 2 ... for Highway and Auto Safety (Advocates) announced today the ... DC offices. The program aims to develop public ... organizations, abiding interest in highway and auto safety. ...
... Board of Directors of ORBIS International is pleased to ... of the New York-based non-profit organization."We are very fortunate ... important time in the organization,s history. ORBIS has reached ... scope--how we deliver our work and maximize operational efficiency. ...
... hold the key, study finds , , MONDAY, Feb 2 (HealthDay ... treat and prevent colitis-associated cancer (CAC), a new study suggests. ... cells in the immune system, plays a key role in ... mice done at the University of California, San Diego, School ...
Cached Medicine News:Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Foundation Kicks off First-Ever PLS Awareness Month 2Health News:Saint Joseph's Adds Renowned Cardiothoracic Surgeon 2Health News:Saint Joseph's Adds Renowned Cardiothoracic Surgeon 3Health News:Allstate and Advocates for Highway and Auto Safety Unveil Public Policy Fellowship Program 2Health News:Allstate and Advocates for Highway and Auto Safety Unveil Public Policy Fellowship Program 3Health News:ORBIS International Appoints New President 2
... Designed To Hold & Support A Dropping Lens ... & Phacoemulsification To ,Continue. Can ... Of A Cyclodialysis Spatula To Reach Into ... Salvage Lens Fragments With One Instrument. ...
... Are Available In Two Models: One Is Direct ... Jaws Close. The Other Model Is Reverse ... Compressed The Jaws Open., ,The Forceps Are 22g, ... Through A 1.1mm Incision. These Forceps Allow The ...
... Designed To Dial An Exact Extension Of ... Maximum Visibility, With Titanium Handle & Spring. ... In Tissue, And Can Also Be Dialed ... Autoclaveable, Made In The USA, Handle Guaranteed ...
... The 0.1mm Pierce Tip Opening ... Flap, Without The Need For A Separate Cystotome. ... Grasping Positions Without Elevating The Incision.,The Distal Jaws ... Blades Help To Prevent Inadvertent Pick Up Of ...
Medicine Products: